A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This clinical trial is testing a new medication called rezatapopt, either alone or with pembrolizumab, to see how well it fights various advanced solid tumors. It is designed for patients whose cancer carries a specific genetic change known as the TP53 Y220C mutation.
Adults (and teens aged 12-17 with special approval) who have advanced solid tumors with the TP53 Y220C mutation and have already tried at least one prior cancer treatment may be eligible. Participants must also have good organ function and be well enough to carry out daily activities.
Participants will receive the study medication, rezatapopt, and some may also receive pembrolizumab, an immunotherapy drug that helps the immune system fight cancer. Doctors will closely monitor participants' safety, overall health, and how well the treatment works against the cancer.
This study is currently recruiting patients at medical centers in locations such as Irvine, La Jolla, and Los Angeles, California.
- 1Tests the study drug rezatapopt for advanced cancers with a specific TP53 Y220C mutation.
- 2Open to patients who have already received at least one prior cancer treatment.
- 3Currently recruiting participants at multiple locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.